MedTrace Logo

ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT00030524 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2012-10-30

No results posted yet for this study

Summary

RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of colorectal cancer.

PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have locally advanced or metastatic colorectal cancer that has not responded to chemotherapy.

Conditions

Interventions

DRUG

gefitinib

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Chris H. Takimoto, MD, PhD · The University of Texas Health Science Center at San Antonio

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2003-09-30
Completion
2003-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030524 on ClinicalTrials.gov